ESR1 and breast carcinoma: More recently, De Mattos-Arruda et al. profiled 7–26 samples per patient from autopsies of 10 patients (5 ER+/HER2-, 3 ER+/HER2+, 1 ER-/HER2+, 1 TNBC) with therapy-resistant breast cancer [9].